MyFinsight
Home
About
Contact
urgn: the income statement
Download
Download image
Comprehensive loss
-$33,330K
(-42.40%↓ Y/Y)
Unrealized income (loss) on
investments
$17K
(-93.63%↓ Y/Y)
Net loss
-$33,347K
(-40.87%↓ Y/Y)
Income tax benefit
(expense)
-$1,054K
(-1258.24%↓ Y/Y)
Zusduri
$1,779K
Jelmyto
$25,703K
Loss before income
taxes
-$34,401K
(-45.88%↓ Y/Y)
Interest and other
income, net
$979K
(-62.33%↓ Y/Y)
Revenue
$27,482K
(9.04%↑ Y/Y)
Interest expense on
long-term debt
$3,373K
(23.96%↑ Y/Y)
Financing on prepaid
forward obligation
$4,621K
(-21.88%↓ Y/Y)
Operating loss
-$27,386K
(-56.09%↓ Y/Y)
Gross profit
$24,204K
(6.39%↑ Y/Y)
Cost of revenue
$3,278K
(33.63%↑ Y/Y)
Selling, general and
administrative expenses
$37,582K
(29.86%↑ Y/Y)
Research and development
expenses
$14,008K
(23.36%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)